The chart: Why: Hims & Hers said it would soon stop selling commercially available compounded versions of popular GLP-1 drugs
These services can assess a patient's medical history, provide prescriptions when necessary, and guarantee adequate follow-up care
doi: 10.1016/j.bbr.2019.112359 [DOI] [PubMed] [Google Scholar] 84.Mehta BK, Singh KK, Banerjee S
The clinical evidence: tirzepatide versus semaglutide head to head Opinions are cheap
Insights 8 9 6 2 3 4 5 In late March, the Stanford Center for Digital Health convened a workshop of clinicians, researchers, tech developers, and industry stakeholders, to explore "how digital tools, artificial intelligence, and lifestyle interventions can support a more holistic and patient-centered approach to metabolic health for individuals using GLP-1 therapies." This is the report that came out of that workshop.